Besides, given that STAT3 is made up of distinct domains and activated by receptor tyrosine kinases, or receptor associated kinases, or non-receptor kinases, or diverse cytokines, synthetic agents targeting STAT3 signaling are mainly classified into the following categories in ovarian cancer: 1) direct inhibitors targeting the domains of STAT3; 2) indirect inhibitors targeting the upstream factors. The gene discussed is STAT3; the disease is ovarian carcinoma.